Neoadjuvant chemotherapy (NAC) is a standard treatment option for locally advanced breast cancer, especially preferred for human epidermal growth factor receptor 2 (HER2)-enriched or triple-negative breast cancer with a tumor size > 2 cm and/or axillary lymph node metastasis [1]. This evidence concerns the gene ERBB2 and breast carcinoma.